Multiple Sclerosis (Ms) - Related Resources

Cochrane reviews

Interferon beta prevents the conversion from first event suggesting a demyelinating episode to clinically definite multiple sclerosis Recombinant Interferon Beta for Delaying Conversion of the First Demyelinating Event to Multiple Sclerosis.
Intravenous periodic high dose methylprednisolone appears to reduce long-term disability progression in relapsing-remitting multiple sclerosis Corticosteroids for the Long-Term Treatment in Multiple Sclerosis.
Cyclophosphamide (CFX) may not prevent the risk of worsening in disabled patients with progressive multiple sclerosis (MS) in the long term, and major adverse effects are common Cyclophosphamide for Multiple Sclerosis.
There is insufficient evidence for the use of any treatment for ataxia or tremor in multiple sclerosis Treatment for Ataxia in Multiple Sclerosis.
Cognitive behavioural approaches may be beneficial in helping people to adjust to and cope with having MS and in the treatment of associated depression. Other psychological interventions may also be helpful Psychological Interventions for Multiple Sclerosis.
Multidisciplinary rehabilitation programmes do not change the level of impairment, but can improve the experience of people with MS in terms of activity and participation Multidisciplinary Rehabilitation for Adults with Multiple Sclerosis.
There is no convincing evidence to support pharmacologic intervention as an effective treatment for memory disorder in multiple sclerosis Pharmacologic Treatment for Memory Disorder in Multiple Sclerosis.
Statins appear not to be effective as an adjunctive therapy in multiple sclerosis Statins for Multiple Sclerosis.
There appears to be no long-term benefit of intravenous corticosteroids for the recovery to normal visual acuity, visual field or contrast sensitivity in acute optic neuritis Corticosteroids for Acute Optic Neuritis.
Interferon beta does not appear to prevent the development of permanent physical disability in secondary progressive multiple sclerosis Interferon Beta for Secondary Progressive Multiple Sclerosis.
Memory rehabilitation is probably not effective on memory function or functional abilities in multiple sclerosis Memory Rehabilitation in Multiple Sclerosis.
The effects of beta-interferons and glatiramer acetate are similar in relapsing-remitting multiple sclerosis regarding clinical and magnetic resonance imaging (MRI) parameters during two to three years. However, beta-interferons limit more effectively the increase in MRI lesion burden as compared with GA .

Other evidence summaries

Magnetic resonance imaging may be of limited value in ruling in or ruling out early diagnosis of multiple sclerosis in patients with suspected disease Magnetic Resonance Imaging for the Early Diagnosis of Multiple Sclerosis.

Clinical guidelines

Multiple sclerosis. National clinical guideline for diagnosisand management in primary and secondary care. National Institute for Health and Clinical Excellence (NICE) http://guidance.nice.org.uk/CG8

Literature

Compston A, Coles A. Multiple sclerosis. Lancet 2008 Oct 25;372(9648):1502-17. [PubMed]
Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007 Jun 21;356(25):2622-9. [PubMed]

Primary/Secondary Keywords

Related resources

section name header

References

Multiple Sclerosis (Ms) - Related Resources

Cochrane reviews

Other evidence summaries

Clinical guidelines

Literature